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Abstract 25 
 Vaccines against viral infections have been proposed to reduce antibiotic prescribing 26 
and thereby help control resistant bacterial infections. However, by combining published data 27 
sources, we predict that pediatric live attenuated influenza vaccination in England and Wales 28 
will not have a major impact upon antibiotic consumption or health burdens of resistance. 29 
30 
 3 
Introduction 31 
 Antibiotic use drives the spread of antibiotic resistance. A substantial proportion of 32 
antibiotic prescriptions are unnecessary because they are written to treat conditions that are 33 
either self-limiting or non-bacterial in etiology (1). Since influenza is often treated 34 
inappropriately with antibiotics, expanding access to influenza vaccines has been proposed as 35 
a means of reducing unnecessary prescribing and preventing resistant infections (2). 36 
In 2013, England and Wales began rolling out the live attenuated influenza vaccine 37 
(LAIV) for 2–16-year-old children (3). Here, we estimate the potential impact on antibiotic 38 
prescribing and antibiotic resistance.  39 
 40 
Methods 41 
Our age-stratified analysis assumes that some influenza cases lead to general 42 
practitioner (GP) consultations and some GP consultations lead to antibiotic prescriptions. 43 
We focus on community antibiotic use as the driver of resistance, as hospitalizations for 44 
influenza are rare relative to GP consultations (4). 45 
Influenza-attributable consultations — For our base-case influenza-attributable 46 
consultation rate, we use previous estimates from a time-series statistical attribution analysis 47 
over the 1995–2009 UK flu seasons (5), yielding a population-wide average of 14.7 48 
influenza-attributable GP consultations per 1000 person-years (Table 1). For our uncertainty 49 
analysis (Appendix Table), we use a lower estimate of 11.8 per 1000, derived from a 50 
longitudinal study in England over 2006–2011 (6), and a higher estimate of 21.4 per 1000, 51 
derived from a time-series statistical analysis for England and Wales over 2000–2008 (4). 52 
Prescriptions per consultation — For our base-case analysis we use a previous UK 53 
average estimate of 726 antibiotic prescriptions for every 1000 influenza-attributable GP 54 
consultations (5). For our uncertainty analysis, we use a lower estimate of 313 per 1000, 55 
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based on electronic health records of prescriptions within 30 days of a consultation for 56 
influenza-like illness (ILI) or acute cough in England over 2013–2015 (7). 57 
Vaccine impact — In our base-case analysis, we assume that LAIV prevents 49% of 58 
symptomatic influenza cases on average, from a previously published mathematical model of 59 
pediatric LAIV in England and Wales which assumes 50% uptake and either 70% (matched 60 
years) or 42% (unmatched years) efficacy among 2–16-year-olds (3). This reduction is 61 
consistent with a pilot study comparing consultation rates in treatment versus control areas 62 
before and after LAIV rollout (8). For our uncertainty analysis, we use lower and upper 63 
estimates of 32% and 63% fewer influenza cases from the same model, assuming an uptake 64 
of 30% and 70%, respectively. 65 
Link between antibiotics and resistance — We use linear regression to predict the per-66 
country health burden of each resistant strain as a function of the country’s rate of primary-67 
care antibiotic consumption, using previously published health burden estimates across 68 
EU/EEA countries in 2015 for 16 resistant bacterial strains (9). The regression slope predicts 69 
the impact of reducing antibiotic consumption by a defined amount, assuming that resistant 70 
infections add to—rather than replace—susceptible infections (10). 71 
Economic cost of resistance — We adopt a published cost estimate of $1415 per 72 
resistant infection (2016 USD) (11), adjusted for inflation and health care purchasing power 73 
parity for the UK to £520 (2015 GBP). 74 
Further details — We use Monte Carlo sampling to explore uncertainty across 75 
estimates for consultation rate, prescribing rate and LAIV impact, weighting age groups 76 
using demographics for England and Wales in 2015. Analysis code and data are available at 77 
github.com/nicholasdavies/laiv_amr_ew. Additional details are in the Appendix. 78 
79 
 5 
Results 80 
We find that LAIV administered to 2–16-year-olds has the potential to reduce 81 
antibiotic consumption by 5.3 (95% highest density interval: 3.7–7.0) prescriptions per 1000 82 
person-years (Table 1) across the population of England and Wales. This is equivalent to 83 
0.8% of the total antibiotic dispensation rate in English primary care in 2015. For comparison 84 
with secular trends, this rate has fallen by 2.5% each year from 2012 to 2018 (Appendix 85 
Figure). Focusing on vaccine recipients only, we estimate that the direct effectiveness of 86 
LAIV on antibiotic consumption is 5.8 (4.1 – 7.5) fewer prescriptions per thousand person-87 
years in unmatched years and 9.9 (7.0 – 13) in matched years. 88 
Although 0.8% is a small decrease in antibiotic use, there may be an appreciable 89 
impact on the cost-effectiveness of pediatric LAIV if the health burdens of resistance are 90 
substantial enough (Figure 1). We estimate that LAIV has the potential to reduce resistance-91 
attributable disability-adjusted life years (DALYs) by 642, cases by 432 and deaths by 22 per 92 
year in England and Wales (Table 2), with averted DALYs spread relatively evenly across 93 
the 7 causative pathogen species analyzed (Figure 2A). We estimate a yearly cost saving of 94 
£224K for averted resistant infections. When compared with the projected incremental cost 95 
(program cost minus health care saving) of pediatric LAIV at £63.6M, and its projected 96 
impact of saving 27,475 quality-adjusted life years (QALYs) and averting 799 deaths yearly 97 
(3), accounting for resistance will not substantially increase the cost-effectiveness of pediatric 98 
LAIV in this setting. Our uncertainty analysis (Figure 2B) identifies the consultation rate as 99 
having the greatest influence over the impact of LAIV on health burdens of resistance. 100 
 101 
Discussion 102 
Our estimates for the foreseeable reduction in antibiotic prescribing from the LAIV 103 
program in England and Wales may seem surprisingly low, given that sore throat, cough, and 104 
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sinusitis together account for 53% of all inappropriate prescribing, which in turn comprises at 105 
least 9–23% of all prescribing in England (1). However, many viral and bacterial pathogens 106 
cause these symptoms. By one estimate, influenza causes only 11% of GP consultations for 107 
acute respiratory illness in England (4), so it may be optimistic to expect influenza 108 
vaccination to substantially reduce antibiotic use in the UK. 109 
Our base-case estimate of 726 antibiotic prescriptions per 1000 influenza-attributable 110 
consultations is more than double what electronic health records suggest (Methods). One 111 
explanation is that this estimate, derived from statistical attribution of antibiotic prescriptions 112 
to influenza circulation over 1995–2009 (5), feasibly includes prescribing for infections 113 
secondary to influenza infection, such as otitis media, sinusitis and pneumonia. Also, 114 
antibiotic use in England has declined since this time—by 22% from 1998 to 2016 (12). 115 
Accordingly, our base-case results should be interpreted as the maximum potential reduction 116 
by LAIV of antibiotic use. Conversely, in the FluWatch study only 8% of consultations for 117 
ILI resulted in influenza or ILI being medically recorded (6), and so electronic health records 118 
may not reliably reflect prescribing rates for influenza. 119 
In randomized trials, the direct effect of influenza vaccines on vaccinated children has 120 
ranged from a 44% reduction in antibiotic prescriptions (Italy) to a 6% increase (United 121 
States), both over the 4-month period following vaccination, while estimates of the impact 122 
over entire populations (all ages, vaccinated and unvaccinated) range from 11.3 fewer 123 
prescriptions per 1000 person-years in Ontario to 3.9 fewer in South Africa and Senegal 124 
(Appendix). This variation can be ascribed to differences in: vaccine efficacy and coverage, 125 
risk factors among the study population, influenza circulation, existing patterns of antibiotic 126 
use, and methodology; estimates of vaccine impact on antibiotic consumption may not be 127 
generalizable across settings.  128 
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Our framework estimates the impact of influenza vaccination on resistance using the 129 
relationship between influenza circulation and antibiotic use in England and Wales, and can 130 
be adapted to other settings for which the strength of this relationship can be quantified. An 131 
alternative approach would be to correlate LAIV uptake, rather than influenza circulation, 132 
directly with antibiotic use. Challenges with this approach include appropriately controlling 133 
for confounding factors in the relationship between vaccine uptake and antibiotic use, and 134 
quantifying the effect of herd immunity. However, consistent with our approach, UK-specific 135 
empirical estimates have suggested little or no effect of LAIV uptake on prescribing. A self-136 
controlled case series study found that 2–4-year-old LAIV recipients in the UK took 13.5% 137 
fewer amoxicillin courses in the 6 months following vaccination (13), while an LAIV pilot 138 
study detected no difference in prescribing rates for respiratory tract infections between 139 
treatment groups (14). No single vaccine is likely to substantially reduce inappropriate 140 
antibiotic use in the UK. 141 
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Tables 212 
Table 1. Projected impact of pediatric LAIV on antibiotic prescription rates, England and 213 
Wales* 214 
Age  
group 
Influenza-attributed 
consultation rate† 
Prescriptions per 
consultation 
Direct prescribing rate 
reduction, unmatched‡  
Direct prescribing rate 
reduction, matched‡ 
LAIV  
impact§ 
Overall prescribing 
rate reduction¶ 
0–6m 29.7 (23.7 – 35.9) 0.597 (0.474 – 0.719) — — 0.574 (0.501 – 0.651) 10.2 (7.03 – 13.5) 
6m–4y 29.7 (23.7 – 35.9) 0.597 (0.474 – 0.719) 7.46 (5.31 – 9.64) 12.4 (8.85 – 16.1) 0.663 (0.618 – 0.714) 11.8 (8.31 – 15.4) 
5–14y 22.1 (17.6 – 26.7) 0.588 (0.466 – 0.708) 5.46 (3.89 – 7.06) 9.11 (6.48 – 11.8) 0.754 (0.709 – 0.794) 9.81 (6.97 – 12.8) 
15–44y 12.8 (10.2 – 15.4) 0.676 (0.536 – 0.814) 3.64 (2.59 – 4.70) 6.06 (4.31 – 7.83) 0.446 (0.394 – 0.502) 3.86 (2.66 – 5.09) 
45–64y 12.4 (9.84 – 14.9) 0.805 (0.639 – 0.970) — — 0.423 (0.374 – 0.484) 4.22 (2.90 – 5.58) 
65y+ 12.2 (9.67 – 14.7) 0.857 (0.680 – 1.03) — — 0.477 (0.397 – 0.561) 4.97 (3.34 – 6.68) 
Overall 14.7 (11.7 – 17.7) 0.726 (0.576 – 0.875) 5.80 (4.13 – 7.49) 9.86 (7.01 – 12.9) 0.494 (0.446 – 0.549) 5.32 (3.74 – 7.00) 
*All estimates reported as mean (95% highest density interval). 215 
†Per 1000 people per year in England and Wales. 216 
‡Reduction in antibiotic prescriptions among vaccinees per 1000 vaccine recipients, not accounting for herd immunity, separately for 217 
unmatched and matched seasons. 218 
§Reduction in influenza cases assuming a 50% uptake among 2–16-year-olds, accounting for herd immunity. 219 
¶Per 1000 people per year in England and Wales, accounting for herd immunity. 220 
 221 
Table 2. Projected impact of pediatric LAIV on health burdens of antibiotic resistance, 222 
England and Wales* 223 
 Estimated 2015 burden Projected reduction in burden from LAIV 
DALYs 46039 642 (450 – 842) 
Cases 47080 432 (303 – 566) 
Deaths 1930 22 (16 – 29) 
*Reductions reported as mean (95% highest density interval). 224 
225 
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Figure legends 226 
 227 
Figure 1. Estimated health burdens of antibiotic-resistant infections plotted against the 228 
overall antibiotic consumption in primary care for 30 European countries, 2015. The United 229 
Kingdom is circled. 230 
 231 
Figure 2. A) Estimated DALYs attributable to resistant infections averted by pediatric LAIV 232 
in England and Wales, stratified by causative pathogen; the entire width of the bar is the 233 
current burden, with potential reductions highlighted in black and reported next to each bar. 234 
B) One-way uncertainty analysis, showing the impact on DALYs averted of alternative 235 
assumptions concerning the rate of influenza-attributable GP consultations, the pediatric 236 
uptake of LAIV, the rate of antibiotic prescribing per GP consultation, and how the impact of 237 
prescribing on health burdens is attributed (see Methods and Appendix for more details). 238 
Attributable deaths
Attributable DALYs
Resistant cases
10 20 30
10 20 30
10 20 30
0
1
2
3
4
0
2
4
0.00
0.05
0.10
0.15
0.20
Primary care antibiotic consumption (DDD per thousand person−days)
In
cid
en
ce
 (p
er
 1
00
0 
pe
rs
on
−y
ea
rs
)
Statistical
model
Prescription
rate
Vaccine
uptake
Consultation
rate
300 400 500 600 700 800 900
DALYs averted
−163
−191
−18
−99
−111
−42
−18
S. pneumoniae
Acinetobacter spp.
Enterococcus spp.
P. aeruginosa
K. pneumoniae
S. aureus
E. coli
0 10000 20000 30000
Attributable DALYs
 1 
Impact of pediatric influenza vaccination on 
antibiotic resistance in England and Wales 
Chungman Chae, Nicholas G. Davies, Mark Jit, and Katherine E. Atkins 
Appendix 
 
 
 
Contents 
1. Influenza-attributable GP consultations .................................................................. 2	
2. Rate of antibiotic prescribing given an influenza-attributable GP consultation ....... 3	
3. Impact of LAIV on rates of GP consultation ............................................................ 4	
4. Age-stratified rates for uncertainty analysis ............................................................ 4	
Appendix Table. .......................................................................................................... 4	
5. Prediction of prescription rate impact on resistance burdens ................................. 5	
6. Economic calculations ............................................................................................ 6	
7. Secular trends in antibiotic prescribing rates .......................................................... 6	
Appendix Figure ......................................................................................................... 7	
8. The impact of influenza vaccination on antibiotic use in different settings ............. 7	
 
 2 
1. Influenza-attributable GP consultations 
1.1 Base-case estimate — From Fleming et al. (1) Table 2, consultations for 
respiratory disease broadly defined attributable to either influenza A or B. Age 
groups reported by Fleming et al. differ from those used in this study, so we adapt 
estimates of Fleming et al. by assuming that reported rates are constant within an 
age group, and that half of children under 12 months old are under 6 months old. 
Fleming et al. do not directly report confidence intervals in measured rates (instead, 
variation between flu seasons is reported), so we assume that uncertainty in the 
influenza-attributable GP consultation rates follows a normal distribution. We assume 
that the standard deviation of any consultation rate derived from this source is 
always S times the mean rate, where S is estimated from Fig. 2 of Fleming et al. (1) 
by assuming that the width of the 95% confidence intervals on this figure are 
equivalent to 1.96 times the standard deviation of an associated normal distribution, 
and that the standard deviation of influenza-attributable GP visits is (a2 + b2)1/2 where 
a is the standard deviation of influenza A-attributable consultations and b is the 
standard-deviation of influenza B-attributable consultations. S is then the mean 
relative standard deviation, calculated in this manner, across all study years. 
1.2 Low estimate — Rates of PCR confirmed influenza are estimated from Hayward 
et al. (2), Tables S2 and S3, taking the mean over the five winter flu seasons 
reported (i.e. excluding the Summer 2009 pandemic flu period), assuming that the 
reported rates of PCR confirmed influenza in the form B (A – C) represent a 
triangular distribution with B as the peak (mode) and A – C as the 95% highest 
density interval (using a triangular distribution rather than a normal distribution allows 
us to account for skew). Then, the probability of a GP visit given PCR-confirmed 
illness is taken from Table S6 of the same source. We correct for low numbers by 
assuming a “base proportion” of 12/82 as the measured proportion of PCR 
confirmable influenza episodes resulting in a GP visit, which comes from the overall 
number of reported GP visits for 5–64-year-olds with PCR-confirmed influenza. To 
account for uncertainty in measurement, we draw the “base rate” of GP consultation 
given PCR-confirmable influenza for 5–64-year-olds from a beta distribution with 
parameters α = 12 + 1, β = 82 – 12 + 1 (i.e. assuming a uniform prior); to account for 
the observation that this rate is higher in young children and the elderly (Table S6), 
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we add 0.12 to this rate for under-5s and over-65s. The annual influenza-attributable 
rate of GP consultation for a given age group is then the product of the PCR-
confirmable influenza incidence and the rate of GP consultation given PCR-
confirmable influenza. 
1.3 High estimate — These are taken from Cromer et al. (3), Table 4, assuming that 
reported 95% confidence intervals represent 1.96 times the standard deviation of a 
normal distribution. 
2. Rate of antibiotic prescribing given an influenza-attributable GP 
consultation 
2.1 Base-case estimate — From Fleming et al. (1) Table 2, by dividing the rate of 
antibiotic prescribing by the rate of influenza-attributable GP consultations, assuming 
a normal distribution for the final rate with the same relative standard deviation 
derived in 1.1 above. 
2.2 Low estimate — From Pouwels et al. (4) Table 3, which reports that 48% of 
consultations for acute cough and 29% of consultations for influenza-like illness 
result in a systemic antibiotic prescription within 30 days. We assume that 88.1% of 
influenza-attributable consultations are for ILI (hence having a 29% prescription rate) 
and the rest are for acute respiratory infection without fever (2) (hence having a 48% 
prescription rate), which yields an overall (crude) prescribing rate of 31.3%. 
To calculate age-stratified values, we assume prescribing for under-5s is about 20% 
less, and for over-45s is about 20% more, than prescribing in 5–44-year-olds, 
consistent with the results of Fleming et al. (1), Meier et al. (5), and Pitman et al. (6). 
That is, we draw a value d from a normal distribution with mean 0.2 and standard 
deviation 0.05, and assume that the relative prescribing rate for under-5s is (1 – d) 
times the rate for 5–44-year-olds, while the relative prescribing rate for over-45s is (1 
+ d) times the rate for 5–44-year-olds. 
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3. Impact of LAIV on rates of GP consultation 
We use fitted models from Baguelin et al. (7) projecting the impact of LAIV on 
influenza cases in different age groups, assuming either a 50% uptake (base-case 
estimate), 30% uptake (low estimate), or 70% uptake (high estimate).  
4. Age-stratified rates for uncertainty analysis 
We summarize the base-case and uncertainty-analysis estimates of age-stratified 
consultation rates, prescription rates, and LAIV impact in the Appendix Table below. 
 
Appendix Table. Summary of base-case and alternative estimates for uncertainty 
analysis for the influenza-attributed GP consultation rate (per 1000 person-seasons 
in England and Wales), prescriptions per influenza-attributable GP consultation, and 
reduction in influenza cases owing to rollout of LAIV. 
Age 
group 
Influenza-attributed  
consultation rate 
Prescriptions  
per consultation 
LAIV  
impact 
 low base high low base low base high 
0-6m 
32.2 
(17.4 – 48.4) 
 
 
29.7 
(23.7 – 35.9) 
 
 
73.6 
(70.6 – 76.7) 
 
 
0.238 
(0.203 – 0.273) 
 
 
0.597 
(0.474 – 0.719) 
 
 
0.390 
(0.330 – 0.447) 
 
 
0.574 
(0.501 – 0.651) 
 
 
0.694 
(0.616 – 0.767) 
 
 
6m-4y 
32.2 
(17.4 – 48.4) 
 
 
29.7 
(23.7 – 35.9) 
 
 
60.9 
(59.2 – 62.6) 
 
 
0.238 
(0.203 – 0.273) 
 
 
0.597 
(0.474 – 0.719) 
 
 
0.469 
(0.433 – 0.517) 
 
 
0.663 
(0.618 – 0.714) 
 
 
0.779 
(0.739 – 0.821) 
 
 
5-14y 
21.0 
(9.87 – 33.3) 
 
 
22.1 
(17.6 – 26.7) 
 
 
38.7 
(37.7 – 39.8) 
 
 
0.238 
(0.203 – 0.273) 
 
 
0.588 
(0.466 – 0.708) 
 
 
0.552 
(0.507 – 0.591) 
 
 
0.754 
(0.709 – 0.794) 
 
 
0.855 
(0.828 – 0.885) 
 
 
15-44y 
10.6 
(4.99 – 16.9) 
 
 
12.8 
(10.2 – 15.4) 
 
 
18.8 
(18.4 – 19.1) 
 
 
0.298 
(0.290 – 0.305) 
 
 
0.676 
(0.536 – 0.814) 
 
 
0.280 
(0.247 – 0.321) 
 
 
0.446 
(0.394 – 0.502) 
 
 
0.585 
(0.526 – 0.655) 
 
 
45-64y 
6.68 
(3.16 – 10.6) 
 
 
12.4 
(9.84 – 14.9) 
 
 
18.3 
(18.0 – 18.6) 
 
 
0.357 
(0.336 – 0.377) 
 
 
0.805 
(0.639 – 0.970) 
 
 
0.262 
(0.227 – 0.298) 
 
 
0.423 
(0.374 – 0.484) 
 
 
0.562 
(0.497 – 0.632) 
 
 
65y+ 
8.45 
(4.06 – 13.2) 
 
 
12.2 
(9.67 – 14.7) 
 
 
5.82 
(5.56 – 6.08) 
 
 
0.357 
(0.336 – 0.377) 
 
 
0.857 
(0.680 – 1.03) 
 
 
0.306 
(0.250 – 0.368) 
 
 
0.477 
(0.397 – 0.561) 
 
 
0.608 
(0.516 – 0.692) 
 
 
Overall 
11.8 
(6.68 – 17.3) 
 
 
14.7 
(11.7 – 17.7) 
 
 
21.4 
(20.9 – 21.9) 
 
 
0.313 
(0.313 – 0.313) 
 
 
0.726 
(0.576 – 0.875) 
 
 
0.323 
(0.289 – 0.358) 
 
 
0.494 
(0.446 – 0.549) 
 
 
0.626 
(0.572 – 0.686) 
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5. Prediction of prescription rate impact on resistance burdens 
5.1 Defined daily doses per prescribed antibiotic course — We assume that each 
prescription comprises 7 defined daily doses (DDD), as 7 days is the typical duration 
of antibiotic treatment for upper respiratory tract infections (8). 
5.2 Main scenario — We use total primary care antibiotic consumption (ATC code 
J01C) for European countries for 2015 from the ECDC (9) as the predictor variable, 
and per-country median health burden (DALYs, cases, or deaths) attributed to each 
of 16 resistant strains analyzed by Cassini et al. (10) as the outcome variable, in a 
series of country-level linear regressions from which we separately predict the 
impact of reducing overall prescribing by a defined amount. For each country, we 
normalize each resistant-strain-specific health burden to the total number of 
bloodstream infections caused by the species in question prior to performing the 
regression in order to control for differences in the population and the per-capita 
incidence of infection between countries. 
To estimate the total number of bloodstream infections caused by a given species in 
a given country, we begin by taking the maximum of the number of total tested 
isolates recorded by the ECDC for that country and species. Then we correct that 
figure according to the estimated population coverage for that country and species to 
the ECDC (i.e. an estimate of what fraction of the population is covered by the 
hospitals submitting resistance testing data to national surveillance programs which 
then report their data to the ECDC). For example, for S. pneumoniae infections in the 
United Kingdom in 2015, 1095 isolates were tested for penicillin non-susceptibility, 
1077 isolates were tested for macrolide non-susceptibility, and 1060 isolates were 
tested for combined non-susceptibility to both penicillins and macrolides. 
Additionally, these isolates were reported as covering an estimated 21% of the entire 
population of the UK. Accordingly, we estimated the total number of bloodstream 
infections by S. pneumoniae in the UK as max(1095, 1077, 1060) / 0.21 = 1095 / 
0.21 ≈ 5214. 
An alternative method whereby health burdens were normalized to the population of 
each country produced similar results (a mean reduction of 714 instead of 642 
DALYs, 362 instead of 432 cases, and 24 instead of 22 deaths). 
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5.3 Alternative scenario 1 — Rather than using the overall antibiotic consumption for 
each country as the sole predictor in the regression model, we also built a separate 
series of models where we used as predictors each country’s consumption of 
tetracyclines (J01AA), extended spectrum penicillins (J01CA), beta-lactamase 
sensitive penicillins (J01CE), and macrolides (J01FA), as these four classes 
comprise the majority of antibiotics prescribed for sore throat and cough (11). We 
assume that for a given reduction in the overall prescription rate x, there is a 
reduction 0.0620x in tetracycline prescribing, 0.4752x in extended spectrum penicillin 
prescribing, 0.2793x in beta-lactamase sensitive penicillin prescribing, and 0.1835x 
in macrolide prescribing. This predicted a smaller impact upon resistance than the 
main scenario (4.1) and comprises the “low-effect” statistical model for the 
uncertainty analysis (Figure 2B, main text). 
5.4 Alternative scenario 2 — We follow the same procedure as in 4.2, but if any 
predictor variable is negatively correlated with a resistance related health burden (i.e. 
the best fitting linear model suggests that decreasing use of that antibiotic would 
increase resistance), we remove it from the linear regression and rerun the model, 
continuing this process until all predictors are positively associated with the outcome 
variable. If more than one variable has a negative association in a given round, all 
are removed for the next round. This predicted a larger impact upon resistance than 
the main scenario (4.1) and comprises the “high-effect” statistical model for the 
uncertainty analysis (Figure 2B, main text). 
6. Economic calculations 
To convert between US and UK health care expenditures, we use hospital-service 
price level indices for health care purchasing power parity published by the OECD 
(12) (see their Fig. 1). 
7. Secular trends in antibiotic prescribing rates 
Data from NHS Digital show that community antibiotic use in England has decreased 
by approximately 2.5% per year from 2012 to 2018 (Appendix Figure). 
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Appendix Figure. Antibiotic use in England has fallen by approximately 2.5% each 
year from 2012 to 2018. 
8. The impact of influenza vaccination on antibiotic use in different settings 
A systematic review (13) found that in randomized trials, the direct effect of influenza 
vaccines on vaccinated children has ranged from a 44% reduction in antibiotic 
prescriptions in Italy (14) to a 6% increase in the United States (15), both over the 4-
month period following vaccination. Published estimates of the impact over entire 
populations (all ages, vaccinated and unvaccinated, i.e. incorporating both direct and 
indirect protection) range from 11.3 fewer prescriptions per 1000 person-years in 
Ontario (16) to 3.9 fewer in South Africa and Senegal (17). 
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